Introducing the Exercise Wheel and the Consensus Recommendations for managing Type 1 Diabetes during exercise are the focus of this conversation between host Kate Neal - Clinical Services Manager at Insulet - and Dr. Othmar Moser - a leading expert in exercise physiology and metabolism from the University of Bayreuth and the University of Graz.

There is new guidance developed by European Association for the Study of Diabetes (EASD) and International Society for Pediatric and Adolescent Diabetes (ISPAD), which provide evidence-based recommendations for managing glucose levels during planned and unplanned physical activities using AID Systems like Omnipod 5 – hear what they are and how they’ll impact your patients on this episode of Within Range.

Dr Moser shares strategies for insulin dosing and carbohydrate consumption to maintain optimal glycemic levels during exercise and explains how to empower patients with practical advice using the AID wheel. The wheel is a tool developed by the authors of the consensus guidance, which address patient concerns around the fear of hypoglycemia. It’s a visual way of explaining how planned and unplanned activities are going to impact glucose levels, and by giving detailed recommendations on adjusting insulin dosage, it helps HCPs and patients manage their physical activity more confidently and safely.

(This episode was recorded live at Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam.)

Note: The information in this podcast is accurate to the date of recording as of 03/20/2025. Dr. Othmar Moser received a fee from Insulet for taking part in this Podcast, views and opinions Dr. Moser expresses in this podcast are his own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com. Omnipod 5 may not be available in your country.

INS-OHS-05-2025-00095 v1.0

Omnipod® 5 provides impressive quality of life improvements for people living with diabetes (PWD)

Recorded at the 60th Annual EASD Scientific Meeting in Madrid, Spain, our host, Cindy Pickering, brings you a conversation with Professor Jean-Pierre Riveline. Prof. Riveline is a senior practitioner in diabetology-endocrinology at Lariboisière hospital as well as a Professor in endocrinology, and the Leader of the Centre Universitaire du Diabète et de ses Complications (CUDC), Lariboisière Hospital in Paris, France. Together Cindy and Prof. Riveline discuss revolutionary AID technology and the impressive impact that Omnipod 5 is making on both glycemia and quality of life, especially through simplicity. Some references to the Insulet Sponsored Symposium at EASD are made and for those interested in watching the recording it can be accessed via www.omnipod.com.

Note: The Podcast was recorded on September 12th 2024 and therefore content reflects information of that time. In France, Omnipod 5 is currently approved for use in patients with type 1 diabetes with HbA1c level ≥ 8% and being treated with CSII for more than 6 months and although Prof. Riveline refers to “laws changing” he meant the reimbursement scope recommended in HTA guidelines have been updated. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved, for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com Omnipod 5 may not be available in your country.

Recorded at the 60th Annual EASD Scientific Meeting in Madrid, Spain, our host, Cindy Pickering, brings you a conversation with Dr. Jackie Elliott. Dr. Elliott is the clinical lead for diabetes at Sheffield Teaching Hospitals in the United Kingdom. Together Cindy and Dr. Elliott discuss revolutionary AID technology and how the simplicity of Omnipod 5 is changing clinical practice. Dr. Elliott describes some impactful case examples of how Omnipod 5 has improved outcomes for not only the person living with diabetes but has also given freedom back to the whole family. Some references to the Insulet Sponsored Symposium at EASD are made and for those interested in watching the recording it can be accessed here: [link to recording here].

Note: The information in this podcast is accurate to the date of recording as of 12th September 2024. Dr. Jackie Elliott received a fee from Insulet for taking part in this Podcast, views and opinions expressed in this podcast are her own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked, UKCA marked, Health Canada approved, and TGA approved, for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com Omnipod 5 may not be available in your country.

INS-OHS-11-2024-00076 v1.0

Recorded at the ADA 84th Scientific Sessions in Orlando, Florida, host Kate Neal brings you a conversation with Cari Berget. Cari is a leading expert in diabetes and technology as a Pediatric Nurse and diabetes educator from the Barbara Davis Center in Denver, Colorado. Together Kate and Cari discuss revolutionary AID technology and the impact on pediatric patient outcomes. Cari highlights initiation and implementation strategies she uses to manage nearly 1,000 pediatric patients on Omnipod 5 and other AID systems. Cari introduces the audience to the PANTHER® Program and describes the development and use of the PANTHERTOOL®, a resource to help HCPs understand and optimize the use of diabetes technologies. For more information about the PANTHER® Program please visit https://www.pantherprogram.org/omnipod-5

Note: The information in this podcast is accurate to the date of recording as of 06/22/2024. Cari Berget received a fee from Insulet for taking part in this Podcast, views and opinions Cari expresses in this podcast are her own and do not necessarily reflect those of Insulet. This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings. Omnipod 5 is CE Marked for use in Type 1 diabetes in people ages 2 years and up. For a complete description of Omnipod 5 including indications, contraindications and important safety information for the UK please visit: https://www.omnipod.com/en-gb/safety For other regions, please refer to country specific statements at www.omnipod.com

Omnipod 5 may not be available in your country.

INS-OHS-08-2024-00159 v1.0